P316 COMPARATIVE EFFICACY, SAFETY AND TOLERABILITY OF DEXIBUPROFEN AND IBUPROFEN IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE  by Baliga, V.P. et al.
Osteoarthritis and Cartilage Vol. 14, Supplement B S171
P314
EFFECTIVENESS OF SODIUM HYALURONATE (500-730
KDA) FOR PAIN ASSOCIATED WITH OA OF THE
SHOULDER: APPLICATION OF THE OMERACT-OARSI
RESPONSE CRITERIA TO THE HUPS STUDY
R. Altman1, M. Daley2
1University of California Los Angeles School of Medicine, Los
Angeles, CA, 2sanofi-aventis, Bridgewater, NJ
Purpose: We conducted post-hoc analyses of OA patients in the
Hyalgan® Use in Painful Shoulder (HUPS) Study to investigate
application of the OMERACT-OARSI treatment response criteria
to these findings, reported previously.
To our knowledge this is the first application of these criteria to
hyaluronan use in patients with pain associated with OA of the
shoulder.
Methods: We investigated application of Proposition D of the
OMERACT-OARSI criteria to both pain on movement (100-mm
VAS, n=286) and night pain (n=285) in OA patients from the
HUPS ITT population. Patients who received either 3 or 5 weekly
injections of sodium hyaluronate (HYL) were pooled for this anal-
ysis and compared to those who received 5 weekly injections of
phosphate-buffered saline (PBS). For both of these pain param-
eters, the Shoulder Rating Questionnaire (SRQ) daily activities
scale served as the function domain, and SRQ VAS served as
the global assessment domain. Both the 2- and 3-level responder
definitions were used.
Results: For VAS pain on movement (HYL, n=192; PBS, n=94),
HYL patients demonstrated greater treatment response than
PBS in both the 2-level (131/192, 68% vs. 50/94, 53%) and 3-
level (high responder, 100/192 [52%] vs. 32/94 [34%]; moderate
responder, 31/192 [16%] vs. 18/94 [19%]) responder definitions.
These results were consistent for VAS night pain in both the
2-level and 3-level responder definitions.
Conclusions: Our application of the OMERACT-OARSI treat-
ment responder criteria to the HUPS study further support the
effectiveness of HYL in patients suffering from pain on movement
and/or night pain associated with OA of the shoulder.
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PHARMACOLOGICAL TREATMENT OF KNEE
OSTEOARTHRITIS IN PRIMARY CARE
M. Acasuso-Diaz1, J. Vidal-Lorenzo1, F. Galdo2
1SAP S Jose Sergas, La Coruña, Spain, 2H.U. Juan Canalejo,
La Coruña, Spain
Purpose: To determine the main drugs prescribed by physi-
cians in an urban Primary Care center in La Coruña (Spain) for
treatment of patients with knee osteoarthritis.
Methods: Clinical charts of patients diagnosed with knee os-
teoarthritis and attended throughout 2004 were reviewed, and
patients meeting ACR criteria were selected. A total of 350
patients were diagnosed with knee osteoarthritis, out of which
207, 153 (74%) women and 54 (26%) men, could be evaluated.
40 patients (19.3%) showed right knee involvement whereas
34 (16.4%) showed left knee involvement. There was bilateral
involvement in 133 patients (64.25%).
Results: Three drug groups were evaluated: non-steroid anti-
inflammatories (NSAIDS), paracetamol, and symptomatic slow-
acting drugs (SYSADOA), considering as such glucosamine sul-
phate, chondroitin sulphate and diacerein.
58 patients (29%) were using drugs belonging to the three
groups; 45 (22.5%) were using NSAIDS and paracetamol; 30
(15%) were using NSAIDS and SYSADOA, 28 (14%) were
just using NSAIDS; 15 (7.5%) were using paracetamol and
SYSADOA; 15 (7.5%) only paracetamol and 9 (4.5%) only
SYSADOA. 104 (50.24%) patients were using topical pharmaco-
logical treatment.
Conclusions: Most of the patients - 103 (51.5%) - are treated
in our center with a combination of a SYSADOA and one or two
fast-acting drugs (either NSAIDS or paracetamol, or both). As
monotherapy, NSAIDS were used the most.
Topical treatment was used on a regular basis by half of the
patients.
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1Glenmark Pharmaceuticals Ltd, Mumbai, India, 2Grant Medical
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Purpose: To compare the efficacy, safety and tolerability of oral
dexibuprofen and ibuprofen in the management of adult Indian
patients with osteoarthritis of knee.
Methods: A prospective, open-label, two-group, comparative,
multicentric study was undertaken in 238 adult Indian pa-
tients,(30 to 70 years) with a clinical diagnosis of osteoarthri-
tis of the knee. The study was conducted in 5 centers across
the country after approval by the respective Institutional boards
amnd obtaining written informed consent from all patients. Pa-
tients fulfilling the inclusion and exclusion criteria were treated
with either Dexibuprofen 400mg- or Ibuprofen 600mg- both one
tablet three times a day for 4 weeks as per the randomization
schedule. The primary efficacy variable of the present study were
improvements in the Western Ontario and McMasters (WOMAC)
individual osteoarthritis (OA) indices and Composite Index (for
pain, stiffness and physical function) and the Visual Analog
Scale (VAS) scores (for pain). Secondary efficacy variable was
improvement in Patient’s and Physician’s global assessment of
efficacy of therapy. General clinical safety was monitored by
the incidence of treatment-emergent adverse events, physical
examination, assessments of vital signs and routine laboratory
tests.
Results: A total 225 (113 in Dexibuprofen and 112 patients in
ibuprofen group) patients completed the study were included in
the analysis while 13 patients (5 in dexibuprofen group and 8 in
inbuprofen group) were lost to follow-up and considered as drop-
outs. Both the drugs provided sustained relief of osteoarthritic
symptoms compared to baseline. There was a reduction of 89.9%
in mean pain score (WOMAC index) in the Dexibuprofen group
which was slightly more than 86.1% observed in the Ibuprofen
after 4 weeks of treatment. A significant reduction of 86.2% was
observed in the mean VAS pain score in Dexibuprofen group
which was significantly greater (p<0.05) as compared to 76.2%
observed in the Ibuprofen group at the end of the 4th week.
Therapy with dexibuprofen showed greater efficacy with regard
to reducing mean scores of stiffness, physical function, VAS pain
scores and mean total WOMAC Index scores as compared to
therapy with racemic Ibuprofen. According to both the investi-
gators’ and patients’ global assessment of efficacy 68.1% and
69.0% of total cases respectively treated with Dexibuprofen rated
efficacy as good to very good which was greater as compared
to 51.7%to 58.1% respectively reported in the Ibuprofen group.
Dexibuprofen was better tolerated by patients as compared to
therapy with racemic ibuprofen in this study. Lesser number of
patients treated with dexibuprofen (19.5%) reported mild to mod-
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erate GI adverse events compared to 30.8% patients treated with
racemic ibuprofen.
Conclusions: The results confirmed that dexibuprofen i.e. S(+)-
isomer of ibuprofen in a dose of 1200mg/day was more effica-
cious and better tolerated as compared to ibuprofen 1800 mg/day
and could therefore be a more suitable option in the symptomatic
treatment of patients with osteoarthritis of the knee
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THE REVIEW OF THE SEVEN PAPERS ABOUT LATERAL
WEDGED INSOLE WITH SUBTALAR STRAPPING FOR
MEDIAL COMPARTMENT OSTEOARTHRITIS OF THE
KNEE
Y. Toda, N. Tsukimura
Toda Orthopedic Rheumatology Clinic, Osaka, Japan
Purpose: We developed of a lateral wedged insole with elastic
strapping of the subtalar joint (the strapped insole) for a treatment
of medial compartment osteoarthritis of the knee (knee OA). In
this presentation, we would like to introduce summaries of our
seven published articles about the strapped insole from 2001 to
2006.
Methods: The subjects were the following: 1) the effect on lower
extremity alignment (J Rheumatol, 2001), 2) the relationship
between participants’ characteristics and efficacy (J Rheumatol
2002), 3) the specific symptomatic efficacy (Arthritis Rheum,
2002), 4) the optimal elevation of wedge (Arch Phys Med Rehabil,
2004), 5) the six month follow-up (Arthritis Rheum, 2004), 6) the
optimal duration of daily wear (Osteoarthritis Cartilage, 2005)
and 7) the two year follow-up (Osteoarthritis Cartilage, 2006).
Results: 1) Participants wearing the strapped insole demon-
strated significantly decreased femorotibial angle and signifi-
cantly improved VAS in comparison with baseline assessments.
2) A significant correlation was observed between lower extrem-
ity lean body mass per body weight and symptomatic relief of
OA of the knee. 3) The efficacy brought about pain reduction
(at night, upon awakening, and on standing from a seated posi-
tion) and increased the maximum distance of ambulation. 4) For
constant routine use, the 12mm elevation wedged insole with
subtalar strapping may be more comfortable and effective than
the 8 or 16mm elevation wedges. 5) The strapped insole main-
tained the valgus correction of the femorotibial angle in patients
with varus knee OA for six months, indicating a longer-term clini-
cal improvement. 6) The remission score of Lequesne index was
significantly improved in the participants treated with a strapped
insole for between five and ten hours each day compared with
that found in the participants treated with the insole for more than
10 hours each day. 7) The strapped insole maintained the valgus
correction of the femorotibial angle in patients with varus knee
OA for two years. If the insole maintains FTA for more than two
Fig. 1. The strapped insole.
years, it may restrict the progression of degenerative articular
cartilage lesions of knee OA.
Conclusions: A conservative therapy such as use of an insole
that provides a low cost, effective compliment or alternative to
surgical treatment would be a very useful adjunct to the care of
these patients and of benefit to the health care economy.
P318
PROSPECTIVE STUDY OF THE SAFETY AND EFFICACY
OF HYLAN G-F 20 (SYNVISC®) IN PATIENTS WITH
SYMPTOMATIC SHOULDER OSTEOARTHRITIS WITHOUT
ROTATOR CUFF TEAR
E. Laprelle1, P. Goupille2, P. Hardy3, F. Hagena4, F. Goebel5,
F. Bailleul6, E. Noël7
1Centre de Médecine et Traumatologie du Sport, Mérignac,
France, 2CHRU Hôpital Trousseau, Tours, France, 3Hôpital
Ambroise Paré, Boulogne-Billancourt, France,
4August-Viktoria-Klinik, Bad Oeynhausen, Germany,
5Martin-Luther-Universität, Halle, Germany, 6Genzyme Europe,
St. Germain-en-Laye, France, 7Centre Orthopédique Santy,
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Purpose: To evaluate the safety and efficacy of hylan G-F 20
viscosupplementation in patients with symptomatic osteoarthritis
(OA) of the shoulder without rotator cuff tear.
Methods: Prospective, multi-center, open study in patients with
gleno-humeral OA (confirmed by X-ray) and no major rotator
cuff tear (confirmed by MRI or arthroscan). At baseline, patients
had to score between 40-90 on the Patient-completed Shoulder
OA Pain VAS (0 - 100 mm). Patients received one intra-articular
injection of 2 ml of hylan G-F 20 and were given an option
of a second and final 2 ml injection if their pain remained
between 40-90 mm on the VAS after 1, 2 or 3 months. Injections
were done under fluoroscopic guidance (maximum of 1 ml of
contrast product). Patients were followed for 6 months after the
final injection. As rescue medication, patients could only take
paracetamol up to 4 g per day, except on the day of or the
day before a study visit.All treatment emergent adverse events
(AEs) were recorded. The primary efficacy endpoint was change
from baseline (at final injection) in the Shoulder OA Pain VAS
at 3 months after the final injection. Secondary endpoints were
Shoulder OA Pain VAS scores at all other time-points, WOOS
scale, Patient’s and Physician’s Global OA assessment (VAS),
and health-related quality of life (SF-36).
Results: Thirty-three patients (18 M; 15 F) were enrolled and
received a first injection of hylan G-F 20. Sixteen patients (48%)
received a second injection. The mean age was 56.7 years
(range 38-80). 85% of patients had idiopathic shoulder OA.
Twenty-nine patients completed the study. Overall, treatment
with hylan G-F 20 was well tolerated. Eight patients (24.2%) had
a treatment related AE of the target shoulder. All were of mild or
moderate intensity, the majority consisting of shoulder pain and
injection site pain. There was a statistically significant decrease
in Shoulder OA Pain VAS score from 61.2 mm at Baseline to 32.5
mm at Month 3 (p<0.001, paired t-test), which was maintained
at 6 months follow-up (32.3 mm). The decrease was statistically
significant at all time points. Patients who received only 1 injection
demonstrated a greater decrease at 3 months (-33.2 mm) than
patients with 2 injections (-18.8 mm). The secondary efficacy
endpoints showed similar results. Of the total study population,
18 patients (60%) were responders (i.e. at least a 50% decrease
in shoulder OA pain) after 3 months. 75% of patients receiving 1
injection were responders after 3 months.
Conclusions: Treatment of OA of the shoulder with intra-articular
hylan G-F 20 injections is well tolerated. Treatment with hylan
G-F 20 significantly decreases pain which is maintained for up to
6 months.
